GLP-1 weight-loss drugs have quickly become some of the most sought-after medications in the United States, but their price tags have also made them one of the most difficult benefits for employers ...

Add Yahoo as a preferred source to see more of our stories on Google. A clinical trial for diabetes that pit orforglipron, a diabetes and weight-loss pill developed by Eli Lilly, against oral ...

Wall Street is enamored of pharmaceutical giant Eli Lilly and its GLP-1 products right now. This pharma peer has a a more modest P/E, more attractive yield, and a solid payout ratio. Eli Lilly was ...

ALLENTOWN, Pa. - News of multi-national pharmaceutical giant Eli Lilly's move into the Lehigh Valley continues to reverberate. This is especially true for Lehigh Carbon Community College. The school ...

Novo Nordisk shares look cheap, but execution and management changes weigh on investor confidence. Eli Lilly’s stronger GLP-1 growth and consistency support its premium versus Novo’s conditional value ...

If you've spent any time online over the last few weeks, you've probably seen a video featuring a man walking up to strangers and telling his "computer" to perform various actions on them in a series ...

Buddy Guy displays a youthful spirit during his Tiny Desk that makes you question if he really turns 90 this year. Once the music starts, his subtle speaking voice transforms into a mighty instrument, ...

Amazon Pharmacy (NASDAQ: AMZN), a full-service digital pharmacy that delivers medications quickly and directly to customers' homes, today announced expanded access to the new Zepbound® KwikPen® ...

Novo Nordisk shares sank after the Danish drugmaker suffered a setback in its battle with Eli Lilly to dominate the market for weight-loss drugs.

LLY is likely to see stronger demand for its GLP-1 drugs as Medicare expands coverage and the company prepares to launch an oral obesity treatment.